Isotechnika Pharma Inc IPHAF

RE: With a pssible 4 billion dollar market

[rfk67]

No offense but you guys are draming when you talk of $3 or $5 in my opinion.  Roche walked away from what is the most lucrative indication by far and their decision should at least tell us that voclo is not a slam dunk for renal.  ISA is now over a bit of a barrel unless there are multiple parties that they are talking to but I think it more likely that they will try to find a single serious company and then try to negotiate the takeout of ISA at as high a price as possible.  My bet is a bit over $1 though I am hoping for more.